Overview

Lansoprazole in Preterm Infants With Gastroesophageal Reflux (GER)

Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
0
Participant gender:
All
Summary
This study is crossover study to evaluate safety and efficacy of lansoprazole in preterm infants with gastroesophageal reflux.
Phase:
Phase 1/Phase 2
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Seoul National University Hospital
Treatments:
Dexlansoprazole
Lansoprazole
Criteria
Inclusion Criteria:

- preterm infant

- symptoms suspecting gastroesophageal reflux

Exclusion Criteria:

- unstable general conditions due infection or acute illness

- congenital anomaly in upper gastrointestinal tract including esophagus

- drug history of H2, proton pump inhibitor, blocker during last 1 week

- medication of warfarin, carbamazepine, phenytoin, rifampin

- inappropriate clinical conditions judged by researchers